Mumbai, Feb. 9 -- Total operating expenses for the period under review aggregated to Rs 166.80 crore, up 19.0% YoY.

PBIDT improved by 34.1% to Rs 47.40 crore in Q3 FY26 from Rs 35.34 crore in Q3 FY25.

Profit before tax in Q3 FY26 stood at Rs 31.16 crore, up by 38.9% from Rs 22.44 crore recorded in Q3 FY25.

SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag.

Published by HT Digital Content Services with permission from Capital Market....